Graft-versus-Host Disease is a medical condition that occurs when the recipient of stem cells or bone marrow receives tissue that is genetically different. This disorder can also occur for other tissue transplants and even blood transfusions. Damage or inflammation to the liver, gastrointestinal tract and skin rash are some of the symptoms of this disorder.
HOW IS GRAFT-VERSUS-HOST DISEASE DIAGNOSED?
A general physician would consider GVHD in a patient who has had a transplant if they exhibit rash, abdominal cramps and diarrhoea within the first 100 days of the transplant. A biopsy of the skin rash and gastrointestinal tract would be performed to confirm the diagnosis.
HOW IS GRAFT-VERSUS-HOST DISEASE TREATED?
GVHD is treated with glucocorticoids such as prednisone which are administered intravenously.
DID YOU KNOW?
There are several clinical trials that are ongoing in the field of research for the Graft-versus-Host Disease. In 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal as a drug for treating the condition.